100 related articles for article (PubMed ID: 2056230)
1. [The prognosis of ovarian cancer depends on the CA125 value at the end of induction therapy].
Miwa K; Dozono H; Iemura K; Shinmura R; Nakamura Y; Matsumoto T; Ikeda S; Nagata Y
Nihon Sanka Fujinka Gakkai Zasshi; 1991 May; 43(5):557-61. PubMed ID: 2056230
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of factors influencing prognosis in patients with advanced ovarian cancer].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1989 May; 41(5):564-70. PubMed ID: 2754287
[TBL] [Abstract][Full Text] [Related]
3. [Advanced cancer of the ovary. Treatment and results].
Wolff JP; George M; Duvillard P; Michel G; Pejovic MH; Haie C
J Gynecol Obstet Biol Reprod (Paris); 1986; 15(2):231-7. PubMed ID: 3722750
[TBL] [Abstract][Full Text] [Related]
4. [Clinico-morphological characteristics and results of treatment of endometrioid cystadenocarcinoma of the ovary].
Vinokurov VL; Livshits MA; Tsyrlina EV; Kolosov AE
Vopr Onkol; 1983; 29(12):49-56. PubMed ID: 6420990
[TBL] [Abstract][Full Text] [Related]
5. The trend of serum CA125 levels during the first three courses of chemotherapy as a predictor of second-look findings in patients with ovarian carcinoma.
Gadducci A; Ferdeghini M; Bartolini T; Facchini V; Mariani G; Bianchi R; Fioretti P
J Nucl Med Allied Sci; 1989; 33(3):243-6. PubMed ID: 2778499
[TBL] [Abstract][Full Text] [Related]
6. [Changes in CA125 concentration in ovarian cancer patients during the remission state--mean attenuating curve and the effectiveness of surgery and chemotherapy].
Kawai M; Inagaki S; Yamashita H; Imaizumi H; Kakihara M; Arii Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 May; 41(5):537-42. PubMed ID: 2474041
[TBL] [Abstract][Full Text] [Related]
7. [Prognosis estimation score in advanced ovarian cancer].
Kobayashi H; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Nov; 41(11):1783-90. PubMed ID: 2592803
[TBL] [Abstract][Full Text] [Related]
8. [Significance of tumor markers in the treatment of patients with ovarian malignancies].
Tomoda Y; Kano T; Furuhashi Y; Mizuno K; Kamiya N; Mizuno K; Sakakibara K; Ohta M
Gan To Kagaku Ryoho; 1987 Nov; 14(11):3027-33. PubMed ID: 2445293
[TBL] [Abstract][Full Text] [Related]
9. CA54/61 as a marker for epithelial ovarian cancer.
Nozawa S; Aoki D; Yajima M; Tsukazaki K; Kobayashi T; Kimura E; Terashima Y; Inaba N; Takamizawa H; Negishi Y
Cancer Res; 1992 Mar; 52(5):1205-9. PubMed ID: 1737381
[TBL] [Abstract][Full Text] [Related]
10. [Serum CA125 in malignant ovarian tumor--periodical monitoring and correlation with other tumor markers].
Kawai M; Yamashita H; Hayashi T; Kamiya N; Kakihara M; Arii Y
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Mar; 38(3):402-10. PubMed ID: 3457877
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic value of early normalization of CA 125 during chemotherapy in stages III and IV ovarian tumors].
Ferrero JM; Largillier R; Ramaioli A; Heudier P; Teissier E; Namer M
Bull Cancer; 1997 Jul; 84(7):722-8. PubMed ID: 9339198
[TBL] [Abstract][Full Text] [Related]
12. [CA 125 in the diagnosis and evaluation of the efficacy of the treatment of cancer of the ovaries].
Sagan DL; Chebotareva ED; Evtushenko GV
Med Radiol (Mosk); 1989 Jun; 34(6):39-42. PubMed ID: 2739519
[TBL] [Abstract][Full Text] [Related]
13. [Effect of chemotherapy on the prognosis of ovarian cancer].
Sugawa T; Umesaki N; Yajima A; Satoh S; Terashima Y; Ochiai K; Tomoda Y; Kanoh T; Noda K; Yakushiji M
Nihon Sanka Fujinka Gakkai Zasshi; 1992 Sep; 44(9):1135-41. PubMed ID: 1333504
[TBL] [Abstract][Full Text] [Related]
14. [An early detection of the recurrence of serous cystadenocarcinoma of the ovary with the tumor marker CA125 levels].
Usui N; Suzuki M; Takada M
Nihon Sanka Fujinka Gakkai Zasshi; 1992 Jun; 44(6):703-9. PubMed ID: 1506732
[TBL] [Abstract][Full Text] [Related]
15. CA125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma.
Tate S; Hirai Y; Takeshima N; Hasumi K
Gynecol Oncol; 2005 Jan; 96(1):143-9. PubMed ID: 15589593
[TBL] [Abstract][Full Text] [Related]
16. [Primary research on saliva and serum CA125 assays for detecting malignant ovarian tumors].
Chen DX; Li FQ
Zhonghua Fu Chan Ke Za Zhi; 1990 Mar; 25(2):84-5, 123-4. PubMed ID: 2364796
[TBL] [Abstract][Full Text] [Related]
17. Serial determinations of aminoterminal propeptide of type III procollagen (PIIINP) and prognosis in ovarian cancer; comparison to CA125.
Simojoki M; Santala M; Risteli J; Risteli L; Kauppila A
Anticancer Res; 2000; 20(6C):4655-60. PubMed ID: 11205196
[TBL] [Abstract][Full Text] [Related]
18. [New technology of diagnosis of ovarian cancer].
Terashima Y
Gan No Rinsho; 1988 Aug; 34(10):1427-31. PubMed ID: 2845169
[TBL] [Abstract][Full Text] [Related]
19. [A study of localizations and serum data; four tumor markers (CA125, CA19-9, CEA and TPA) in ovarian cancers].
Kataoka A; Yakushiji M
Nihon Gan Chiryo Gakkai Shi; 1990 Jan; 25(1):47-54. PubMed ID: 2157782
[TBL] [Abstract][Full Text] [Related]
20. [Clinical value of a new serum tumor marker CA602 in ovarian cancers].
Suzuki M; Sekiguchi I; Ohwada M; Aida I; Tamada T
Nihon Gan Chiryo Gakkai Shi; 1990 Jul; 25(7):1454-60. PubMed ID: 2170549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
